Studies on the metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry
Staack RF, Fritschi G, Maurer HH.
Department of Experimental and Clinical Toxicology,
Institute of Experimental and Clinical Pharmacology and Toxicology,
University of Saarland, D-66421 Homburg, (Saar), Germany.
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jun 15;773(1):35-46.
ABSTRACTStudies are described on the metabolism and on the toxicological analysis of the piperazine-like designer drug N-benzylpiperazine (BZP, scene name "A2") in rat and human urine using gas chromatography-mass spectrometry (GC-MS). The identified metabolites indicated that BZP was hydroxylated at the aromatic ring and that the piperazine moiety is metabolically degraded. Our systematic toxicological analysis (STA) procedure using full-scan GC-MS after acid hydrolysis, liquid-liquid extraction and microwave-assisted acetylation allowed the detection of the parent compound as well as of the above mentioned metabolites in rat urine after single administration of a dose calculated from the doses commonly taken by drug users. It has also proved to be applicable in authentic clinical or forensic cases. However, it should be considered that BZP is also a metabolite of the medicament piberaline.BZP
MDMA vs BZP and TFMPP
Antidepressant properties of BZP (Trelibet)
Screening for piperazine- and amphetamine-derived designer drugs
MDMA (Ecstasy)-like behavioural effects of N-substituted piperazines
Is BZP neuroprotective against MDMA/Ecstasy-induced neurotoxicity?
The Good Drug Guide
The Hedonistic Imperative
MDMA: Utopian Pharmacology
Critique of Huxley's Brave New World